Health Dashboard

Jul 2025

Discovery — partial panel

Nov 2025

Expanded panel · amenorrhea

Mar 2026

Full picture · protocol launch

Jun 2026

Complete panel + DEXA + RMR

Aug 2026

Phase 3 · Levo · BHRT active

Levothyroxine started July 13, 2026 · 32.5mcg daily. Compounded testosterone 15mg + DHEA 20mg cream started July 27, 2026. September labs will be the first full recheck on all three.

FSH not ordered for June 2026 — add to September draw. Ultrasensitive estradiol (LC/MS/MS, order code 30289) recommended for September.

Active medications — started 2026

Levothyroxine

32.5 mcg / day

Half of 75mcg tablet · daily

Started July 13, 2026

Testosterone (compounded cream)

15 mg / day

Compounded · topical

Started July 27, 2026

DHEA (compounded cream)

20 mg / day

Compounded · topical · combined with testosterone

Started July 27, 2026

Steroid precursor hormones

Pregnenolone

128 ng/dL

Ref: 22–237 · Target: 80+

53↑128

More than doubled — past target

DHEA-S

152 mcg/dL

Ref: 15–205 · DHEA cream started Jul 27

216→218↓152

Recheck Sep — DHEA active

Magnesium, RBC

5.1 mg/dL

Ref: 4.0–6.4 · mid-range

Adequate

Thyroid — Levothyroxine started Jul 13

TSH

4.54 mIU/L

Target: 2.0–3.5 · last drawn Jun 2026

9.94↓4.91↓4.54

Levo active — recheck Sep

TPO antibodies

276 IU/mL

Target: 250–325

468↓464→276

Within target

Free T4

1.0 ng/dL

Ref: 0.8–1.8 · last drawn Jun 2026

0.9→0.8↑1.0

Expect rise with Levo — recheck Sep

Free T3

3.2 pg/mL

Ref: 2.3–4.2

3.2→2.7↑3.2

Clean conversion

Reverse T3

8 ng/dL

Ref: 8–25

Optimal — no T4 pooling

Hormones — BHRT active as of Jul 27

Estradiol (E2)

<30 pg/mL

Follicular ref: 30–144 · last drawn Jun 2026

87↑97↓<30

Recheck Sep — use ultrasensitive assay

Estrone (E1)

23 pg/mL

82↓23

Recheck Sep

Total Estrogen

53 pg/mL

214↓53

Recheck Sep

Free Testosterone

2.0 pg/mL

Target: 4.0–6.0 · last drawn Jun 2026

4.6↓2.1↓2.0

T cream 15mg active — recheck Sep

Total Testosterone

23 ng/dL

Ref: 2–45 · last drawn Jun 2026

35↓27↓23

T cream active — recheck Sep

SHBG

79 nmol/L

Target: 55–65

60↑82↓79

Expect drop with T — recheck Sep

13.1 mIU/mL

28.3↓3.4↑13.1

Recheck Sep

FSH

—

Not ordered June 2026

Add to Sep draw

Progesterone

0.5 ng/mL

Last drawn Jun 2026

0.6→0.5

Recheck Sep

Prolactin

8.9 ng/mL

Stable · normal

AMH

0.01 ng/mL

Ovarian reserve depleted

Iron & Anemia — primary rate limiter

Ferritin

19 ng/mL

Target: 70–100

27↑29↓19

Critical — iron loading active

RBC

3.59 M/uL

3.76↑4.25↓3.59

Normocytic anemia

Hemoglobin

11.3 g/dL

11.8↑13.3↓11.3

Below range

Hematocrit

34.4 %

37.2↑40.6↓34.4

Below range

Serum Iron

63 mcg/dL

131↓63

Low-normal

% Saturation

20 %

39↓20

In range, dropping

IGF-1 & Cortisol

IGF-1

244 ng/mL

Target: 180–250

157↑244

Within target · Z-score 0.2 → 1.2

Cortisol AM

10.7 mcg/dL

18.3↓10.7

Normalized

DEXA + RMR baseline complete — June 19, 2026. BF goal: 18–20%. Prior 24.9% was a Hume Health BIA reading — kept as reference only.

DEXA — total body composition

Total body fat

33.4%

Target: 18–20%

Total mass

194.4 lbs

Fat mass

65.0 lbs

Lean mass

122.8 lbs

BMC (bone)

6.7 lbs

Fat-free mass

129.5 lbs

Regional breakdown

Region	Fat %	Total	Fat	Lean
Arms	34.1%	26.0 lbs	8.8 lbs	16.2 lbs
Legs	34.2%	72.8 lbs	24.9 lbs	45.3 lbs
Trunk	34.2%	84.8 lbs	29.0 lbs	53.9 lbs
Android	36.9%	12.3 lbs	4.5 lbs	7.6 lbs
Gynoid	36.5%	30.9 lbs	11.3 lbs	19.1 lbs

Visceral fat & distribution

VAT volume

33.40 in³

Ideal: 0–52

Healthy range

A/G Ratio

1.00

Optimal: <1.0

At threshold

Bone density

1.442 g/cm²

T-score 3.6 · Z-score 1.8

Excellent

RMR — metabolic baseline

RMR

1,674 kcal/day

BMI

28.73

Maintenance

2,000–2,050 kcal

Suggested deficit

1,650–1,700 kcal

Lipids

Total Cholesterol

215 mg/dL

197191215

Monitor — expect improvement with BHRT

LDL

139 mg/dL

122115139

Rising

HDL

61 mg/dL

616461

Stable

Triglycerides

63 mg/dL

574163

Pristine

Metabolic

Glucose

100 mg/dL

8197100

Borderline

HbA1c

5.3 %

5.45.55.3

Improving

Insulin

11.5 uIU/mL

Optimal

Homocysteine

7.3 umol/L

Excellent

Liver & kidney

AST / ALT

17 / 12

Pristine

eGFR

90–105

Excellent

Urine ACR

3 mg/g

No albuminuria

Omega fatty acids

EPA+DPA+DHA

4.6 % by wt

Optimal: ≥5.5

Upgrading omega-3

Omega-6/3 Ratio

8.6

In range

Autoimmune

ANA Screen

Positive

Watch and wait

ANA Titer

1:80

Recheck 6–12 mo

ANA Pattern

Nucleolar

Monitor

Inflammatory & CBC

hs-CRP

0.3 mg/L

Excellent

ESR

6 mm/h

Normal

WBC

3.5 K/uL

Low-stable

Platelets

291 K/uL

Normal

Vitamin D

38 ng/mL

Target: 60–80

3029↑35↑38

Below target

Selenium

142 mcg/L

Optimal

Zinc

67 mcg/dL

Low-normal

B12

374 pg/mL

MMA confirms adequate use

Folate

18.8 ng/mL

Normal

CoQ10

1.12 ug/mL

Adequate

Magnesium (serum)

1.8 mg/dL

Low-normal

Magnesium RBC

5.1 mg/dL

Adequate

Levothyroxine 32.5mcg started July 13, 2026 · Compounded testosterone 15mg + DHEA 20mg started July 27, 2026.

Phase 3 peptide protocol started August 3, 2026. Tesamorelin paused. MOTS-c replenishment deferred until anemia resolves.

Medications — active prescriptions

Levothyroxine

32.5 mcg / day

Half of 75mcg tablet · daily

Started July 13, 2026

Testosterone (compounded cream)

15 mg / day

Compounded · topical

Started July 27, 2026

DHEA (compounded cream)

20 mg / day

Compounded · topical · combined with testosterone

Started July 27, 2026

Supplements — daily

Selenium selenomethionine 200mcg · Thorne
Zinc bisglycinate Thorne
Vitamin D3 drops 10,000 IU · Thorne
Magnesium glycinate 200mg
NR + Quercetin Phytosome + Trans-Resveratrol 500/250/150mg · Reus Research
Creatine
Collagen powder
Ashwagandha powder
Baja Gold salt
Iron bisglycinate 108mg / 3 caps loading · Thorne
Boron 5mg · Pure TheraPro Rx
DIM + BioPerine 200mg
Resciency Mitochondrial & ATP 4 caps
Timeline Urolithin A 500mg / 2 softgels
Omega-3 high EPA 3 softgels

Peptides — Phase 3 (started Aug 3, 2026)

Morning — Fasted — Daily

KPVDaily

300 mcg · 10 units

Gut barrier health & targeted anti-inflammatory support

Recon: 10mg + 2 mL BAC

BPC-157Daily

500 mcg · 10 units

Angiogenesis, tendon & ligament tissue repair

Recon: 10mg + 2 mL BAC

GlutathioneDaily

200 mg · 20 units

Master cellular antioxidant & hepatic detoxifier

Recon: Vial equiv. + 2 mL BAC

Thymosin Alpha-1Mon / Thu

1.5 mg · 25 units

T-cell maturation & immune system resilience

Recon: 10mg + 2 mL BAC

Midday / Post-Training

TB-500Mon / Thu

1.25 mg · 25 units

Systemic soft-tissue mobility & cellular migration

Recon: 10mg + 2 mL BAC

GHK-Cu (Copper)Daily

2.0 mg · 10 units

Collagen synthesis & extracellular matrix remodeling

Recon: 50mg + 2.5 mL BAC

11:00 PM — Empty Stomach — 5 Days On / 2 Off

CJC-1295 (No DAC)5 on / 2 off

250 mcg · 10 units

Pulsatile growth hormone secretagogue base

Recon: 10mg + 2 mL BAC

Ipamorelin5 on / 2 off

300 mcg · 10 units

Clean, cortisol-flat GH receptor activation

Recon: 10mg + 2 mL BAC

Cognitive — Injection — 20-Day Cycle

CerebrolysinDaily · 20 days on / 3 mo off

10 mL · injectable

Neuroprotection, cognitive enhancement & neuroplasticity

Cycle 1: Aug 6 – Aug 25, 2026 · Day 1 of 20

Paused / deferred

Tesamorelin

Paused — not included in Phase 3

MOTS-c

Replenishment deferred until anemia resolves

5-Amino-1MQ

Deferred until anemia resolves

Log of peptide names, doses, and timing as recorded across protocol documents.

November 17, 2025 — Phase 1 start

Peptide	Dose	Timing
KPV	500 mcg	Morning
BPC-157	250 mcg	Twice daily
TB-500	5 mg	Weekly, 6 weeks
Tesamorelin	2 mg	Nightly
CJC-1295 / Ipamorelin	300 / 300 mcg	Nightly
GHK-Cu (optional)	100 mcg	Daily

January 13, 2026 — Weekly checklist, Weeks 4–12

Peptide	Dose	Timing
KPV	250 mcg	Morning, daily
BPC-157	250 mcg	Evening, daily
Tesamorelin	1 mg (40 units)	Night, empty stomach
CJC-1295 / Ipamorelin	300 mcg	Night, empty stomach
TB-500	500 mcg	Mon + Thu, non-training days

March 30, 2026 — Order + dosing schedule

Peptide	Dose	Timing
CJC-1295 / Ipamorelin	15 units	Morning, fasted
MOTS-c	20 units	Post-workout
Tesamorelin	20 units	Evening, before bed
BPC-157	20 units	Evening, before bed
TB-500	20 units	Evening, before bed

MOTS-c usage note

Peptide	Status
MOTS-c	Used March–May 2026. Replenishment deferred until anemia resolves.

August 3, 2026 — Phase 3 start

Peptide	Dose	Timing
KPV	300 mcg · 10 units	Morning fasted, daily
BPC-157	500 mcg · 10 units	Morning fasted, daily
Glutathione	200 mg · 20 units	Morning fasted, daily
Thymosin Alpha-1	1.5 mg · 25 units	Morning fasted, Mon/Thu
TB-500	1.25 mg · 25 units	Midday/post-training, Mon/Thu
GHK-Cu (Copper)	2.0 mg · 10 units	Midday window, daily
CJC-1295 (No DAC)	250 mcg · 10 units	11pm, empty stomach, 5 on/2 off
Ipamorelin	300 mcg · 10 units	11pm, empty stomach, 5 on/2 off

Composite biological age

33–38

Chronological: 47

Established March 2026 · DEXA bone density (T-score 3.6, Z-score 1.8) reinforces young-skeletal-age component

CV age 32–35 VO2max 48.58 RHR 57 BP 116/79 Bone T-score +3.6 VAT 33.4 in³ (healthy)

Genetic variants

Risk variants confirmed

COMT

DIM + Ca-D-glucarate w/ BHRT

MAO-A

BHRT urgency ↑

AHCY + MAT1A

Methylated B vitamins

SHMT1

Methylfolate required

ACAT

Contextualizes LDL

Normal variants

MTHFR

Normal

MTR / MTRR

Normal

BHMT / CBS

Normal

VDR

Normal

Thyroid ultrasound images — viewer loads from thyroid_ultrasound_viewer.html in the same folder. Use arrow keys or filmstrip to navigate images.

Body composition targets

Current weight

194.4 lbs

Target: 161–163 lbs

Current BF (DEXA)

33.4%

Target: 18–20%

Lean mass

122.8 lbs

Preserve

RMR

1,674 kcal/day

Deficit 1,650–1,700

September 2026 lab targets

TPO antibodies

276 → 250–325

TSH

4.54 → 2.0–3.5

Levo started Jul 13

Free Testosterone

2.0 → 4.0–6.0

T cream started Jul 27

DHEA-S

152 → monitor

DHEA cream started Jul 27

SHBG

79 → 55–65

Ferritin

19 → 70–100

Vitamin D

38 → 60–80

FSH

Add to order

Clinical sequencing

Anemia correction — iron loading active, September confirmation

Levothyroxine 32.5mcg — started July 13, 2026

Compounded testosterone 15mg + DHEA 20mg — started July 27, 2026

Phase 3 peptide protocol — started August 3, 2026

MOTS-c restock decision — after anemia resolves

September 2026 — full panel + FSH + ultrasensitive estradiol

New functional medicine / telehealth provider transition

Health Dashboard

Health Optimization Dashboard